BioXcel Therapeutics, Inc. (BTAI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q3 '24: 214K Q4 '24: 366K Q1 '25: 168K Q2 '25: 120K Q3 '25: 98K Q4 '25: 256K Q1 '26: 206K Q2 '26: 182K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q3 '24: -956K Q4 '24: -466K Q1 '25: 154K Q2 '25: 13K Q3 '25: 87K Q4 '25: 224K Q1 '26: -77K Q2 '26: 160K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '24: -15.3M Q4 '24: -10.5M Q1 '25: -10.1M Q2 '25: -15.9M Q3 '25: -14.2M Q4 '25: -10.3M Q1 '26: -10.2M Q2 '26: -10.2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -13.7M Q4 '24: -10.9M Q1 '25: -7.3M Q2 '25: -19.2M Q3 '25: -30.9M Q4 '25: -12.5M Q1 '26: -12.7M Q2 '26: -14.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 400K 800K 1.2M Q3 '24: 1.2M Q4 '24: 832K Q1 '25: 14K Q2 '25: 107K Q3 '25: 11K Q4 '25: 32K Q1 '26: 283K Q2 '26: 22K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '24: -16.3M Q4 '24: -14.8M Q1 '25: -12M Q2 '25: -12.6M Q3 '25: -18.8M Q4 '25: -14.2M Q1 '26: -11.8M Q2 '26: -6.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '24: -16.3M Q4 '24: -14.8M Q1 '25: -12M Q2 '25: -12.6M Q3 '25: -18.8M Q4 '25: -14.2M Q1 '26: -11.8M Q2 '26: -6.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '24: 1.9M Q2 '24: 2.5M Q3 '24: 2.6M Q1 '25: 4.8M Q2 '25: 7.8M Q3 '25: 14.2M Q1 '26: 23.6M Q2 '26: 30.3M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q3 '24: -115.27 Q4 '24: -25.25 Q1 '25: -12.86 Q2 '25: -12.01 Q3 '25: -9.04 Q4 '25: -5.73 Q1 '26: -4.77 Q2 '26: -2.81 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.